Immunotherapy Gains Ground in Breast Cancer Treatment, Showing Promise Especially for Aggressive Forms
The immunotherapy success rate for breast cancer is rapidly evolving, offering new hope for patients as immune-based treatments reshape oncology. While traditional approaches like chemotherapy, hormone therapy, and targeted therapies remain vital, immunotherapy is emerging as a transformative option, particularly for aggressive subtypes like triple-negative breast cancer (TNBC).
Immunotherapy works by activating the body’s own immune system to recognize and destroy cancer cells. However, breast cancer cells often evade this immune response by exploiting pathways like PD-1 and PD-L1, which suppress immune activity. Checkpoint inhibitors – drugs that block these pathways – are designed to restore immune function and allow the body to attack cancer.
TNBC: The Most Responsive Subtype
Among breast cancer subtypes, TNBC has consistently demonstrated the most significant response to immunotherapy. This is largely due to its tendency to exhibit higher levels of tumor-infiltrating lymphocytes and PD-L1 expression, making it more “visible” to the immune system compared to hormone receptor-positive (HR+) or HER2-positive tumors.
Landmark Trials Demonstrate Efficacy
Significant breakthroughs in immunotherapy for breast cancer have come from trials involving atezolizumab and pembrolizumab. Atezolizumab (Tecentriq) was the first immune checkpoint inhibitor approved for the disease. The IMpassion130 trial, a landmark study, showed that combining atezolizumab with nab-paclitaxel extended progression-free survival in patients with PD-L1-positive metastatic TNBC compared to chemotherapy alone. Median progression-free survival increased from 5.0 months to 7.5 months, representing a 38% reduction in the risk of disease progression, according to research published in the New England Journal of Medicine in 2018.
Later, pembrolizumab (Keytruda) received FDA approval following the KEYNOTE-355 trial, which combined pembrolizumab with chemotherapy in metastatic TNBC. For patients with PD-L1 expression (CPS ≥10), pembrolizumab improved median overall survival from 16.1 to 23.0 months – a 35% increase in survival. Published in The Lancet in 2022, these findings have positioned pembrolizumab as a cornerstone of immunotherapy for PD-L1-positive metastatic TNBC.
Expanding Role in Early-Stage Disease
Immunotherapy is also showing considerable promise in early-stage breast cancer, used in conjunction with chemotherapy to improve surgical outcomes and long-term survival. The KEYNOTE-522 trial demonstrated that combining pembrolizumab with chemotherapy before and after surgery significantly improved both pathologic complete response (pCR) and event-free survival in high-risk early TNBC. Patients receiving pembrolizumab achieved a pCR in 64.8% of cases, compared to 51.2% with chemotherapy alone, and three-year event-free survival improved from 76.8% to 84.5%. This has led to pembrolizumab becoming a standard component of treatment regimens for early-stage TNBC.
Subtype-Specific Response Rates
The immunotherapy success rate varies considerably across breast cancer subtypes. TNBC remains the primary beneficiary, while other forms exhibit more limited results.
In TNBC, immunotherapy combined with chemotherapy achieves objective response rates between 35% and 40% in metastatic, PD-L1-positive disease, and pathologic complete response rates exceeding 60% in early-stage tumors. For HER2-positive breast cancer, research combining checkpoint inhibitors with trastuzumab or other HER2-targeted therapies has yielded response rates of 10–15%. Hormone receptor-positive breast cancer, however, tends to be less immunogenic, with response rates typically below 10%, although ongoing trials exploring combinations with checkpoint inhibitors and CDK4/6 inhibitors aim to improve these outcomes.
Combination Strategies to Enhance Success
Oncologists are actively exploring combination strategies to boost the immunotherapy success rate. Combining immunotherapy with chemotherapy has proven particularly effective, as chemotherapy can increase the release of tumor antigens and enhance immune system recognition. Other promising combinations include immunotherapy with PARP inhibitors for BRCA-mutated tumors, radiotherapy to induce immunogenic cell death, and HER2-targeted agents to increase immune activation.
Overall Outcomes and Influencing Factors
Current evidence indicates that the immunotherapy success rate is strongly influenced by disease stage, tumor biology, and biomarker expression. Across all subtypes, the average response rate ranges from 20% to 30%. However, in PD-L1-positive TNBC, response rates can reach up to 40% in metastatic disease and over 60% in early-stage cases when combined with pembrolizumab. The presence or absence of PD-L1 expression is a critical factor, with patients lacking PD-L1 expression or having hormone receptor-positive disease generally experiencing limited benefits.
Key factors influencing immunotherapy response include PD-L1 expression, the presence of tumor-infiltrating lymphocytes, high tumor mutational burden (TMB), and BRCA mutations – all of which enhance immune detection. These biomarkers are now routinely assessed to determine patient eligibility.
Safety and Tolerability
While immunotherapy offers significant benefits, it can cause immune-related side effects, including thyroid inflammation, pneumonitis, hepatitis, and skin reactions, occurring in approximately 15–20% of patients. These events are typically manageable with corticosteroids. Importantly, immunotherapy generally offers a more favorable safety profile compared to traditional chemotherapy, particularly with long-term use.
The Future of Immunotherapy in Breast Cancer
The future of immunotherapy in breast cancer is bright. Researchers are developing new immune checkpoint inhibitors targeting LAG-3, TIGIT, and TIM-3, alongside personalized cancer vaccines and CAR T-cell therapies directed at breast-specific antigens like MUC1 and HER2. Combining these approaches with genetic and immune profiling is expected to further increase the immunotherapy success rate, potentially expanding its use beyond TNBC to other subtypes.
In conclusion, the immunotherapy success rate for breast cancer is highly variable and dependent on tumor characteristics. The most substantial benefits are currently observed in PD-L1-positive triple-negative breast cancer, where pembrolizumab and atezolizumab have demonstrated remarkable results, with response rates ranging from 35–65% depending on disease stage. While results remain modest in HER2-positive and hormone receptor-positive cancers, ongoing research and innovative combination strategies are rapidly expanding immunotherapy’s impact. With continued scientific progress, the immunotherapy success rate for breast cancer is poised to rise, offering renewed hope to patients across the spectrum of disease.
You can learn more about advancements in cancer treatment on the OncoDaily YouTube channel.
